Hydventia (Hydrocortisone)

Hydrocortisone binds to intracellular glucocorticoid receptors, forming a complex that enters the nucleus and alters gene transcription. This up‑regulates anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines, enzymes, and adhesion molecules, thereby dampening immune responses and decreasing tissue inflammation.

The specific dose of Hydventia is determined by the prescribing clinician based on the patient’s condition, severity, age, and response to therapy. Dosage regimens vary widely, and the prescriber will tailor the amount and frequency to achieve therapeutic goals while minimizing risk.

The safety of hydrocortisone in pregnancy or lactation has not been definitively established. Clinicians weigh potential benefits against possible risks to the fetus or infant. If treatment is essential, the lowest effective dose is generally recommended, and close monitoring is advised.

To order Hydventia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Hydrocortisone has a relatively short half‑life and mimics natural cortisol, making it suitable for physiologic replacement in adrenal insufficiency. Compared with longer‑acting agents such as prednisolone or dexamethasone, hydrocortisone provides less potent anti‑inflammatory effects but offers a more predictable safety profile for dose titration.

Hydventia tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Hydventia is taken orally, usually with water. The tablet may be swallowed whole or, if advised by a healthcare professional, divided or crushed for patients with swallowing difficulties. Administration timing (e.g., morning vs. evening) depends on the therapeutic indication and prescriber instructions.

Serious risks include adrenal crisis if the drug is stopped abruptly, severe infections due to immunosuppression, osteoporosis with long‑term use, and metabolic disturbances such as hyperglycaemia. Patients should be educated to report unexplained fever, severe fatigue, bone pain, or sudden changes in blood pressure.

Hydventia is contraindicated in patients with known hypersensitivity to hydrocortisone or any excipients, those with systemic fungal infections, and individuals receiving live vaccines without appropriate medical guidance. Caution is also advised for patients with uncontrolled diabetes, severe hypertension, or active peptic ulcer disease.